Literature DB >> 22212432

Inhibition of the STAT3 signaling pathway is involved in the antitumor activity of cepharanthine in SaOS2 cells.

Zan Chen1, Chen Huang, Yan-ling Yang, Yi Ding, Han-qiang Ou-Yang, You-yi Zhang, Ming Xu.   

Abstract

AIM: To investigate the molecular mechanisms underlying the antitumor activity of cepharanthine (CEP), an alkaloid extracted from Stephania cepharantha Hayata.
METHODS: Human osteosarcoma cell line SaOS2 was used. MTT assay, Hoechst 33342 nuclear staining, flow cytometry, Western blotting and nude mouse xenografts of SaOS2 cells were applied to examine the antitumor activity of CEP in vitro and in vivo. The expression levels of STAT3 and its downstream signaling molecules were measured with Western blotting and immunochemistry analysis. The activity of STAT3 was detected based on the phosphorylation level of STAT3, luciferase gene reporter assay and translocation of STAT3 to the nucleus.
RESULTS: Treatment of SaOS2 cells with CEP (2.5-20 μmol/L) inhibited the cell growth in a concentration- and time-dependent manner. CEP (10 μmol/L) caused cell cycle arrest at G(1) phase and induced apoptosis of SaOS2 cells. CEP (10 and 15 μmol/L) significantly decreased the expression of STAT3 in SaOS2 cells. Furthermore, CEP (5 and 10 μmol/L) significantly inhibited the expression of target genes of STAT3, including the anti-apoptotic gene Bcl-xL and the cell cycle regulators c-Myc and cyclin D1. In nude mouse xenografts of SaOS2 cells, CEP (20 mg·kg(-1)·d(-1), ip for 19 d) significantly reduced the volume and weight of the tumor.
CONCLUSION: Our findings suggest that inhibition of STAT3 signaling pathway is involved in the anti-tumor activity of CEP.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22212432      PMCID: PMC4010275          DOI: 10.1038/aps.2011.164

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  34 in total

1.  Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies.

Authors:  Kazumasa Morita; Motonobu Nakamura; Miyako Nagamachi; Tatsuo Kishi; Yoshiki Miyachi
Journal:  J Dermatol       Date:  2002-10       Impact factor: 4.005

Review 2.  Recent studies on the biofunctions and biotransformations of curcumin.

Authors:  J K Lin; M H Pan; S Y Lin-Shiau
Journal:  Biofactors       Date:  2000       Impact factor: 6.113

3.  The prevention of lipopolysaccharide-induced pulmonary vascular injury by pretreatment with cepharanthine in rats.

Authors:  K Murakami; K Okajima; M Uchiba
Journal:  Am J Respir Crit Care Med       Date:  2000-01       Impact factor: 21.405

4.  Formation, recognition and bioactivities of a novel G-quadruplex in the STAT3 gene.

Authors:  Sen Lin; Sufang Li; Zan Chen; Xiangwei He; Youyi Zhang; Xiaojie Xu; Ming Xu; Gu Yuan
Journal:  Bioorg Med Chem Lett       Date:  2011-08-06       Impact factor: 2.823

5.  [Antitumor effect of cepharanthin--mechanism of the antimetastatic effect on Lewis lung carcinoma (3LL)].

Authors:  M Ono
Journal:  Gan To Kagaku Ryoho       Date:  1988-02

6.  Cepharanthine activates caspases and induces apoptosis in Jurkat and K562 human leukemia cell lines.

Authors:  J Wu; H Suzuki; Y W Zhou; W Liu; M Yoshihara; M Kato; A A Akhand; A Hayakawa; K Takeuchi; K Hossain; M Kurosawa; I Nakashima
Journal:  J Cell Biochem       Date:  2001       Impact factor: 4.429

7.  Effect of bisbenzylisoquinoline (biscoclaurine) alkaloids on multidrug resistance in KB human cancer cells.

Authors:  N Shiraishi; S Akiyama; M Nakagawa; M Kobayashi; M Kuwano
Journal:  Cancer Res       Date:  1987-05-01       Impact factor: 12.701

8.  Cepharanthin, an alkaloid from Stephania cepharantha, inhibits increased pulmonary vascular permeability in an ovine model of sepsis.

Authors:  Kazunori Murakami; Robert A Cox; Hal K Hawkins; Frank C Schmalstieg; Roy W McGuire; Jeffrey M Jodoin; Lillian D Traber; Daniel L Traber
Journal:  Shock       Date:  2003-07       Impact factor: 3.454

9.  Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor kappaB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjögren's syndrome patients.

Authors:  Masayuki Azuma; Keiko Aota; Tetsuya Tamatani; Katsumi Motegi; Tsuyoshi Yamashita; Yuki Ashida; Yoshio Hayashi; Mitsunobu Sato
Journal:  Arthritis Rheum       Date:  2002-06

10.  Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.

Authors:  Motoi Mukai; Xiao-Fang Che; Tatsuhiko Furukawa; Tomoyuki Sumizawa; Shunji Aoki; Xiao-Qin Ren; Misako Haraguchi; Yoshikazu Sugimoto; Motomasa Kobayashi; Hideo Takamatsu; Shin-Ichi Akiyama
Journal:  Cancer Sci       Date:  2003-06       Impact factor: 6.716

View more
  11 in total

1.  Icaritin suppresses the proliferation of human osteosarcoma cells in vitro by increasing apoptosis and decreasing MMP expression.

Authors:  Xiao-fang Wang; Jun Wang
Journal:  Acta Pharmacol Sin       Date:  2014-03-10       Impact factor: 6.150

2.  Cepharanthine exerts antitumor activity on choroidal melanoma by reactive oxygen species production and c-Jun N-terminal kinase activation.

Authors:  Qi Zhu; Baofeng Guo; Linlin Chen; Qiuye Ji; Hang Liang; Naiyan Wen; Ling Zhang
Journal:  Oncol Lett       Date:  2017-03-29       Impact factor: 2.967

3.  Radiation, inflammation, and immune responses in cancer.

Authors:  Gabriele Multhoff; Jürgen Radons
Journal:  Front Oncol       Date:  2012-06-04       Impact factor: 6.244

4.  Eriocalyxin B Inhibits STAT3 Signaling by Covalently Targeting STAT3 and Blocking Phosphorylation and Activation of STAT3.

Authors:  Xiaokui Yu; Li He; Peng Cao; Qiang Yu
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

5.  The anti-hyperglycemic efficacy of a lipid-lowering drug Daming capsule and the underlying signaling mechanisms in a rat model of diabetes mellitus.

Authors:  Yong Zhang; Xiaoguang Li; Jiamin Li; Qingwei Zhang; Xiaohui Chen; Xin Liu; Yue Zhang; Haiying Zhang; Huan Yang; Yingying Hu; Xianxian Wu; Xin Li; Jiaming Ju; Baofeng Yang
Journal:  Sci Rep       Date:  2016-10-10       Impact factor: 4.379

6.  Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

Authors:  Peter Y Yu; Heather L Gardner; Ryan Roberts; Hakan Cam; Seethalakshmi Hariharan; Ling Ren; Amy K LeBlanc; Hui Xiao; Jiayuh Lin; Denis C Guttridge; Xiaokui Mo; Chad E Bennett; Christopher C Coss; Yonghua Ling; Mitch A Phelps; Peter Houghton; Cheryl A London
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

7.  Determination of cepharanthine in rat plasma by LC-MS/MS and its application to a pharmacokinetic study.

Authors:  Yingbin Deng; Weijun Wu; Sunzhi Ye; Wei Wang; Zhiyi Wang
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

Review 8.  Cepharanthine: An update of its mode of action, pharmacological properties and medical applications.

Authors:  Christian Bailly
Journal:  Phytomedicine       Date:  2019-05-10       Impact factor: 5.340

9.  Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.

Authors:  Jason I Couto; Misty D Bear; Jiayuh Lin; Michael Pennel; Samuel K Kulp; William C Kisseberth; Cheryl A London
Journal:  BMC Vet Res       Date:  2012-12-17       Impact factor: 2.741

10.  Cepharanthine Enhances TRAIL-Mediated Apoptosis Through STAMBPL1-Mediated Downregulation of Survivin Expression in Renal Carcinoma Cells.

Authors:  Sk Abrar Shahriyar; Seon Min Woo; Seung Un Seo; Kyoung-Jin Min; Taeg Kyu Kwon
Journal:  Int J Mol Sci       Date:  2018-10-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.